WO2011080500A3 - New pharmaceutical dosage form for the treatment of gastric acid-related disorders - Google Patents

New pharmaceutical dosage form for the treatment of gastric acid-related disorders Download PDF

Info

Publication number
WO2011080500A3
WO2011080500A3 PCT/GB2010/002335 GB2010002335W WO2011080500A3 WO 2011080500 A3 WO2011080500 A3 WO 2011080500A3 GB 2010002335 W GB2010002335 W GB 2010002335W WO 2011080500 A3 WO2011080500 A3 WO 2011080500A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
dosage form
related disorders
gastric acid
pharmaceutical dosage
Prior art date
Application number
PCT/GB2010/002335
Other languages
French (fr)
Other versions
WO2011080500A2 (en
Inventor
Andreas Fischer
Emil Schwan
Original Assignee
Orexo Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orexo Ab filed Critical Orexo Ab
Publication of WO2011080500A2 publication Critical patent/WO2011080500A2/en
Publication of WO2011080500A3 publication Critical patent/WO2011080500A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

According to the invention there is provided a single unit oral dosage form comprising: (a) a first component comprising a proton pump inhibitor or a pharmaceutically acceptable salt thereof and an enteric substance positioned to protect the proton pump inhibitor from the acidic environment of the stomach; (b) a second component comprising an H2 receptor antagonist or a pharmaceutically acceptable salt thereof; and (c) a physical and/or chemical barrier located between the first and second components, and preventing said components from interacting with each other. The dosage forms of the invention are particularly useful in the treatment of gastric acid secretion-related disorders, such as gastro-esophageal reflux disease.
PCT/GB2010/002335 2009-12-29 2010-12-24 New pharmaceutical dosage form for the treatment of gastric acid-related disorders WO2011080500A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29061209P 2009-12-29 2009-12-29
US61/290,612 2009-12-29

Publications (2)

Publication Number Publication Date
WO2011080500A2 WO2011080500A2 (en) 2011-07-07
WO2011080500A3 true WO2011080500A3 (en) 2011-11-10

Family

ID=43795193

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2010/002335 WO2011080500A2 (en) 2009-12-29 2010-12-24 New pharmaceutical dosage form for the treatment of gastric acid-related disorders

Country Status (1)

Country Link
WO (1) WO2011080500A2 (en)

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997021424A1 (en) * 1995-12-09 1997-06-19 Laboratoire Glaxo Wellcome Chewing gum containing ranitidine
WO1997025066A1 (en) * 1996-01-08 1997-07-17 Astra Aktiebolag Oral pharmaceutical dosage forms comprising a proton pump inhibitor and an antacid agent or alginate
WO2002083132A1 (en) * 2001-04-18 2002-10-24 Orexo Ab Gastric acid secretion inhibiting composition
WO2004035090A1 (en) * 2002-10-16 2004-04-29 Orexo Ab Gastric acid secretion inhibiting composition
US20060165797A1 (en) * 2005-01-12 2006-07-27 Pozen Inc. Dosage form for treating gastrointestinal disorders
JP2007091648A (en) * 2005-09-29 2007-04-12 Eisai R & D Management Co Ltd Pharmaceutical composition containing benzimidazole-based proton pump inhibitor and h2 receptor antagonist
US20090004248A1 (en) * 2007-06-29 2009-01-01 Frank Bunick Dual portion dosage lozenge form
US20090123390A1 (en) * 2007-11-13 2009-05-14 Meritage Pharma, Inc. Compositions for the treatment of gastrointestinal inflammation

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (en) 1978-04-14 1979-10-15 Haessle Ab Gastric acid secretion
IL75400A (en) 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
JPS6150978A (en) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd Pyridine derivative and preparation thereof
AU4640985A (en) 1984-08-31 1986-03-06 Nippon Chemiphar Co. Ltd. Benzimidazole derivatives
SE8804629D0 (en) 1988-12-22 1988-12-22 Ab Haessle NEW THERAPEUTICALLY ACTIVE COMPOUNDS
CA2083606C (en) 1990-06-20 2001-08-21 Arne Elof Brandstrom Dialkoxy-pyridinyl-benzimidazole derivatives, process for their preparation and their pharmaceutical use
SE9002206D0 (en) 1990-06-20 1990-06-20 Haessle Ab NEW COMPOUNDS
SE9301830D0 (en) 1993-05-28 1993-05-28 Ab Astra NEW COMPOUNDS
SE9302396D0 (en) 1993-07-09 1993-07-09 Ab Astra A NOVEL COMPOUND FORM
US5945124A (en) 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997021424A1 (en) * 1995-12-09 1997-06-19 Laboratoire Glaxo Wellcome Chewing gum containing ranitidine
WO1997025066A1 (en) * 1996-01-08 1997-07-17 Astra Aktiebolag Oral pharmaceutical dosage forms comprising a proton pump inhibitor and an antacid agent or alginate
WO2002083132A1 (en) * 2001-04-18 2002-10-24 Orexo Ab Gastric acid secretion inhibiting composition
WO2004035090A1 (en) * 2002-10-16 2004-04-29 Orexo Ab Gastric acid secretion inhibiting composition
US20060165797A1 (en) * 2005-01-12 2006-07-27 Pozen Inc. Dosage form for treating gastrointestinal disorders
JP2007091648A (en) * 2005-09-29 2007-04-12 Eisai R & D Management Co Ltd Pharmaceutical composition containing benzimidazole-based proton pump inhibitor and h2 receptor antagonist
US20090004248A1 (en) * 2007-06-29 2009-01-01 Frank Bunick Dual portion dosage lozenge form
US20090123390A1 (en) * 2007-11-13 2009-05-14 Meritage Pharma, Inc. Compositions for the treatment of gastrointestinal inflammation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FANDRIKS LARS ET AL: "Can famotidine and omeprazole be combined on a once-daily basis?", SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, INFORMA HEALTHCARE, GB, vol. 42, no. 6, 1 January 2007 (2007-01-01), pages 689 - 694, XP008142563, ISSN: 0036-5521, DOI: 10.1080/00365520601026665 *

Also Published As

Publication number Publication date
WO2011080500A2 (en) 2011-07-07

Similar Documents

Publication Publication Date Title
WO2009064460A3 (en) Gastrointestinal delivery systems
ZA200903929B (en) Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
MX2011011480A (en) Orally disintegrating tablet compositions comprising combinations of non-opioid and opioid analgesics.
Scarpignato et al. Proton pump inhibitors: the beginning of the end or the end of the beginning?
WO2012001156A3 (en) Pharmaceutical oral dosage forms comprising dabigatran etexilate and its pharmaceutically acceptable salts
DK2070538T3 (en) Manipulation-resistant oral pharmaceutical dosage forms containing an opioid analgesic
IL193727A0 (en) Dosage forms for administering combinations of drugs
WO2009088414A3 (en) Oral pharmaceutical dosage forms
WO2009153665A3 (en) Inhibitors of the shiga toxins trafficking through the retrograde pathway
WO2011012322A3 (en) Synthesis and use of vildagliptin for the preparation of pharmaceutical dosage forms
NO20085415L (en) Pharmaceutical dosage form containing sustained-release phenylephrine
WO2007105113A3 (en) Use of crf1 receptor antagonists for preparing a drug for treating metabolic syndrome and/or obesity and/or dyslipoproteinemia
BRPI0406987A (en) Medicament for the prevention and / or treatment of atherosclerosis, medicaments for inhibiting vascular smooth muscle cell proliferation, neointimal formation of blood vessels and vascular remodeling, medicament for the prevention of restenosis following percutaneous coronary intervention, and, medicines for the prophylaxis and / or treatment of hypertension or diseases caused by hypertension or diseases caused by hypertension, heart disease, angina pectoris, myocardial infarction, arrhythmia, sudden death, heart failure, cardiac hypertrophy, kidney diseases, diabetic nephropathy, glomerulonephritis, nephrosclerosis, cerebrovascular diseases, cerebral infarction, and cerebral hemorrhage
WO2010012459A3 (en) A process for the preparation of solifenacin salts and their inclusion into pharmaceutical dosage forms
EA200870182A1 (en) APPLICATION OF THE COMBINATION OF MORPHIN AND AT LEAST ONE ANTAGONIST OF OPIATS FOR THE TREATMENT OF OPIATS DEPENDENCE FOR THE PREVENTION OF NON-ORAL OPIATOMA IN ADDICTS
EA201171125A1 (en) ANTAGONIST MINERALOCORTICOID RECEPTOR AND METHODS OF ITS APPLICATION
WO2011080502A3 (en) New pharmaceutical dosage form for the treatment of gastric acid-related disorders
WO2011083402A3 (en) Immediate release compositions of acid labile drugs
WO2011080500A3 (en) New pharmaceutical dosage form for the treatment of gastric acid-related disorders
UA107716C2 (en) A sustained-release pharmaceutical composition for the treatment or prevention of hypertension or normal high blood pressure and renal dysfunction and which contains a 2-phenylth-iazole compound
WO2011080501A3 (en) New pharmaceutical dosage form for the treatment of gastric acid-related disorders
MX2012003310A (en) Use of opioid receptor antagonist for gastrointestinal tract disorders.
RU2015106931A (en) MEDICINE FOR GASTROESOPHAGEAL REFLUX DISEASE
WO2007133476A3 (en) Competitive substrate inhibition to increase drug bioavailability
WO2011035343A3 (en) Phentermine liquid dosage form

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10805279

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10805279

Country of ref document: EP

Kind code of ref document: A2